AMRN Amarin Corp

RNS Number:6338X
Amarin Corporation Plc
01 June 2007



    AMARIN TO PRESENT AT FTN MIDWEST SECURITIES CORPORATION 2007 HEALTH CARE
                                   CONFERENCE



LONDON, United Kingdom, June 1, 2007 Amarin Corporation plc (NASDAQ: AMRN)
("Amarin" or "Company") today announced that Rick Stewart, Chief Executive
Officer, will present at the FTN Midwest Securities Corporation 2007 Health Care
Conference on Tuesday, June 5, 2007 at 3.05 p.m. Eastern Time. The event will be
held from June 5 - June 6, 2007 at the Four Seasons Hotel, New York.


The presentation will be simultaneously webcast and a link will be provided on
Amarin Corporation's website www.amarincorp.com.



About Amarin

Amarin is committed to improving the lives of patients suffering from diseases
of the central nervous system.  Our goal is to be a leader in the research,
development and commercialization of novel drugs that address unmet patient
needs.


Amarin's core development pipeline includes Miraxion for several therapeutic
indications, an oral formulation of apomorphine for treating patients with
advanced Parkinson's disease, a nasal formulation of lorazepam for treating
epilepsy seizures, AMR-109 for memory and cognition, AMR-103 for Parkinson's
disease and our proprietary pre-clinical combinatorial lipid program.


Amarin has its primary stock market listing in the U.S. on NASDAQ ("AMRN") and
secondary listings in the U.K. and Ireland on AIM ("AMRN") and IEX ("H2E"),
respectively.


For press releases and other corporate information, visit the Amarin website at
http://www.amarincorp.com. Information on our website does not form part of this
press release.


Contacts:

Amarin
+44 (0) 207 907 2442
Rick Stewart, Chief Executive Officer
Alan Cooke, President and Chief Financial Officer
investor.relations@amarincorp.com


Investors:
Lippert/Heilshorn & Associates, Inc.
Anne Marie Fields, +1 212 838 3777


Media:

Powerscourt
+44 (0) 207 250 1446
Rory Godson
Victoria Brough


Disclosure Notice:


The information contained in this document is as of June 1, 2007. Amarin assumes
no obligation to update any forward-looking statements contained in this
document as a result of new information or future events or developments. This
document contains forward-looking statements about Amarin's financial condition,
results of operations, business prospects and products in research that involve
substantial risks and uncertainties. You can identify these statements by the
fact that they use words such as "will", "anticipate", "estimate", "expect",
"project", "forecast", "intend", "plan", "believe" and other words and terms of
similar meaning in connection with any discussion of future operating or
financial performance or events. Among the factors that could cause actual
results to differ materially from those described or projected herein are the
following: the success of Amarin's research and development activities,
including the phase III trials with Miraxion in Huntington's disease; decisions
by regulatory authorities regarding whether and when to approve Amarin's drug
applications, as well as their decisions regarding labeling and other matters
that could affect the commercial potential of Amarin's products; the speed with
which regulatory authorizations, pricing approvals and product launches may be
achieved; the success with which developed products may be commercialized;
competitive developments affecting Amarin's products under development; the
effect of possible domestic and foreign legislation or regulatory action
affecting, among other things, pharmaceutical pricing and reimbursement,
including under Medicaid and Medicare in the United States, and involuntary
approval of prescription medicines for over-the-counter use; Amarin's ability to
protect its patents and other intellectual property; claims and concerns that
may arise regarding the safety or efficacy of Amarin's product candidates;
governmental laws and regulations affecting Amarin's operations, including those
affecting taxation; Amarin's ability to maintain sufficient cash and other
liquid resources to meet its operating requirements; general changes in UK and
US generally accepted accounting principles; growth in costs and expenses; and
the impact of acquisitions, divestitures and other unusual items, including
Amarin's ability to integrate its acquisition of Amarin Neuroscience Limited. A
further list and description of these risks, uncertainties and other matters can
be found in Amarin's Form 20-F for the fiscal year ended December 31, 2006,
filed with the SEC on March 5 2007, Amarin's statutory annual report for the
year ended 31 December, 2006 furnished on a Form 6-K to the SEC on May 9, 2007
and in its Reports of Foreign Issuer on Form 6-K furnished to the SEC.


Ends.




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
STRUAAORBBRNRAR

Amarin (LSE:AMRN)
Historical Stock Chart
From Jan 2025 to Feb 2025

Amarin (LSE:AMRN)
Historical Stock Chart
From Feb 2024 to Feb 2025